AU2002257890A1 - Method for replicating the hepatitis C virus - Google Patents

Method for replicating the hepatitis C virus

Info

Publication number
AU2002257890A1
AU2002257890A1 AU2002257890A AU2002257890A AU2002257890A1 AU 2002257890 A1 AU2002257890 A1 AU 2002257890A1 AU 2002257890 A AU2002257890 A AU 2002257890A AU 2002257890 A AU2002257890 A AU 2002257890A AU 2002257890 A1 AU2002257890 A1 AU 2002257890A1
Authority
AU
Australia
Prior art keywords
replicating
hepatitis
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002257890A
Other versions
AU2002257890B2 (en
Inventor
Jean Dubuisson
Gilles Duverlie
Andre Pillez
Czeslaw Wychowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0105732A external-priority patent/FR2824072B1/en
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2002257890A1 publication Critical patent/AU2002257890A1/en
Application granted granted Critical
Publication of AU2002257890B2 publication Critical patent/AU2002257890B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002257890A 2001-04-27 2002-04-25 Method for replicating the hepatitis C virus Ceased AU2002257890B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/05732 2001-04-27
FR0105732A FR2824072B1 (en) 2001-04-27 2001-04-27 PROCESS FOR REPLICATION AND PRODUCTION OF HEPATITIS C VIRUS
PCT/FR2002/001422 WO2002088338A2 (en) 2001-04-27 2002-04-25 Method for replicating the hepatitis c virus

Publications (2)

Publication Number Publication Date
AU2002257890A1 true AU2002257890A1 (en) 2003-04-17
AU2002257890B2 AU2002257890B2 (en) 2008-05-22

Family

ID=8862798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002257890A Ceased AU2002257890B2 (en) 2001-04-27 2002-04-25 Method for replicating the hepatitis C virus

Country Status (12)

Country Link
US (3) US7314710B2 (en)
EP (1) EP1381675B1 (en)
JP (1) JP2004527252A (en)
AT (1) ATE335073T1 (en)
AU (1) AU2002257890B2 (en)
CA (1) CA2445596A1 (en)
DE (1) DE60213578T2 (en)
ES (1) ES2269684T3 (en)
FR (1) FR2824072B1 (en)
MX (1) MXPA03009736A (en)
NZ (1) NZ529037A (en)
WO (1) WO2002088338A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824072B1 (en) * 2001-04-27 2004-03-12 Centre Nat Rech Scient PROCESS FOR REPLICATION AND PRODUCTION OF HEPATITIS C VIRUS
US7223787B2 (en) * 2003-10-21 2007-05-29 Board Of Regents, The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication
EP1801116A1 (en) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV replicon shuttle vectors
EP2162529B1 (en) * 2007-06-08 2019-03-27 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US9580688B2 (en) 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
GB0718446D0 (en) * 2007-09-21 2007-10-31 Prendergast Patrick T Compositions and methods for the treatment of infection
WO2010057013A1 (en) 2008-11-14 2010-05-20 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US20100173281A1 (en) * 2009-01-06 2010-07-08 Roche Palo Alto Llc HCV NS3 protease replicon shuttle vectors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
AU6943994A (en) * 1993-05-04 1994-11-21 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis c virus cell propagation and related methods
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
AU1822195A (en) * 1995-02-10 1996-08-27 Consiglio Nazionale Delle Ricerche Process to "in vitro" propagate the hepatitis c virus (hcv) in non lymphoblastoid animal cell cultures and products thereof
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
DE19915178A1 (en) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C virus cell culture system
US6808876B1 (en) * 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
WO2002038793A2 (en) * 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
FR2824072B1 (en) * 2001-04-27 2004-03-12 Centre Nat Rech Scient PROCESS FOR REPLICATION AND PRODUCTION OF HEPATITIS C VIRUS

Similar Documents

Publication Publication Date Title
AU2002357049A1 (en) Methods for preparing 0-desmethylvenlafaxine
AU2002210450A1 (en) Maintaining virus detection software
HK1070287A1 (en) Hepatitis c virus inhibitors
AU2001282528A1 (en) Compounds having anti-hepatitis c virus effect
AU2003206862A1 (en) Hepatitis b vaccines
HK1066245A1 (en) Method for virus propagation
ZA200306040B (en) Hepatitis B virus treatment.
AU2003260984A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
AU2002257890A1 (en) Method for replicating the hepatitis C virus
AU2292600A (en) Varicella-zoster virus vaccines
EP1298117A3 (en) Method for preparing bromofluorenes
AU2003256404A1 (en) Hepatitis c virus assays
AU2002250101A1 (en) Lithography method
AU2003230790A1 (en) Hepatitis c virus sub-genomic replicons
AU2003289016A1 (en) Method of distinguishing drug-resistance of hepatitis b virus
AU2002354841A1 (en) Engineering oncolytic viruses
AU2002351795A1 (en) Hepatitis x virus antigen
AU2001234644A1 (en) Methods for inactivating viruses
AU2003263028A1 (en) Mouse hepatitis virus detection
GB0111442D0 (en) Method for preparing recombinant virus
AU2002327384A1 (en) Remedies for hepatitis c
AU2006233207A1 (en) Hepatitis C virus inhibitors
AU2002340558A1 (en) Method for inhibiting the replication of viruses
AU2002328495A1 (en) Hepatitis b virus proliferation inhibitor
AU2002342298A1 (en) Methods for inactivating viruses